Login to Your Account



MARCHING TO THE BEAT OF A SINGLE DRUM

Ofirmev sets brisk tempo for $1.3B Cadence Pharmaceuticals acquisition

By Marie Powers
Staff Writer

Tuesday, February 11, 2014
The acquisition of Cadence Pharmaceuticals Inc. by Mallinckrodt plc for $14 per share in cash, or approximately $1.3 billion on a fully diluted basis, demonstrated that a single asset can still beat the drums when it comes to deal terms.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription